Worldwide Rotating Gamma System (RGS) Market: Strategic Imperatives for 2026 Decision-Making

PW Consulting’s latest market research brief on the Worldwide Rotating Gamma System (RGS) market distills the commercial, clinical, regulatory and operational intelligence that hospital systems, radiotherapy providers, medical device manufacturers and investors need to prioritize capital and go-to-market decisions in 2026. Anchored on a 2025 base year and a detailed forecast through 2032, the study combines a robust market model with practical deployment playbooks and vendor-level strategic assessments — intentionally presenting depth while preserving proprietary segment-level tables and revenue matrices for subscribers.
Worldwide Rotating Gamma System (RGS) Market

Market snapshot: momentum and medium-term outlook

RGS adoption has entered a maturation phase characterized by steady market expansion and growing clinical validation. Our market model places the RGS market at USD 348.66 Million in the base year 2025, having expanded meaningfully from the early-decade baseline through a combination of new product introductions, regulatory clearances, and localized clinical studies. Looking forward, the market is forecast to reach approximately USD 507.19 Million by 2032, tracking at a compound annual growth rate of about 5.5% over the forecast horizon. This trajectory reflects both continued capital purchases of systems and the growing share of recurring maintenance and service revenue as installed bases age and treatment protocols broaden beyond traditional intracranial indications.
Worldwide Rotating Gamma System (RGS) Market

Why 2026 is a strategic inflection point

• Regulatory momentum meets real-world adoption. Recent clearances and notifications in major markets have reduced barriers for procurement committees to consider RGS as a viable alternative to conventional static multi-source systems.
• Capital planning cycles. Many hospital systems finalize multi-year capital budgets in late 2025 and early 2026; the availability of validated systems, clearer reimbursement pathways and emerging clinical evidence makes 2026 the key year to commit or defer investments.
• Services and lifecycle economics. As clinical programs mature, purchasers must weigh total cost of ownership — including source management, regulatory compliance and service contracts — not just headline equipment pricing.
• Competitive disruption among vendors. New entrants and refreshed product lines are shifting sales dynamics; providers should expect more options but also more complexity in procurement negotiations.

What the PW Consulting RGS report delivers (practical contents)

The report is designed as an operational toolkit for decision-makers. Highlights include:
Worldwide Rotating Gamma System (RGS) Market

• Proprietary market model and scenario analyses. A bottom-up model that reconciles historical observations with deployment scenarios through 2032, enabling users to stress-test capital and service revenue outcomes under alternative adoption curves.
• Capital procurement playbook. A step-by-step tender and evaluation framework that aligns clinical needs, facility readiness, regulatory constraints and supplier risk to shorten procurement cycles and mitigate scope creep.
• Total cost of ownership (TCO) and ROI calculators. Customizable templates to quantify acquisition, commissioning, source replacement and lifecycle service costs versus anticipated procedure volumes and payer mixes.
• Clinical adoption roadmap. Protocol templates, KPIs for program success, training and credentialing timelines, and evidence generation strategies to accelerate internal approvals and payer conversations.
• Regulatory and reimbursement mapping. Cross-jurisdictional pathways, 510(k)/NMPA filing reference points, and coding/reimbursement guidance for intracranial and extracranial SRS/SBRT use cases.
• Vendor intelligence and negotiation briefs. Strategic supplier profiles, capability matrices, debate-ready questions for RFPs, and recommended contracting guardrails to protect against service and source supply risks.
• Clinical evidence compendium and case studies. Curated summaries of retrospective and prospective studies, including implementation learnings from early adopter centers and pointers for designing local outcomes studies that matter to payers.

Competitive landscape: strategic profiles and implications

The RGS competitive set is concentrated among a handful of specialized manufacturers that combine cobalt-60 source architectures with rotating delivery mechanics and varying levels of image guidance. PW Consulting’s assessment focuses on technological differentiation, regulatory positioning, channel strategies and service economics.

• American Radiosurgery Inc. (San Diego, USA)

  Strengths: Established product family (Vertex360, RGS Orbiter) engineered around cobalt-60 based noninvasive radiosurgery for cranial, spinal and select body indications. The company’s long-standing presence and engineering heritage offer buyers a familiar alternative to other rotating-source platforms.

  Strategic considerations: American Radiosurgery’s advantage lies in proven delivery mechanics and established clinical workflows. Customers should evaluate service network maturity and spare-source logistics when comparing lifecycle economics.

• Akesis Inc. (Concord, USA)

  Strengths: Akesis has rapidly positioned itself with the Galaxy RTi and Gemini360RT systems featuring continuous rotational delivery using thirty cobalt-60 sources and integrated in-plane real-time image guidance. Regulatory milestones have been notable: public notices and clearances have supported entry into the U.S. market.

  Recent developments and implications: In 2024–2025 Akesis achieved regulatory milestones and clinical implementations in the United States, including a notable clinical deployment at a major cancer center in 2025. For purchasers, the Akesis offering introduces compelling operational features (real-time image guidance and rotational dosimetry) but also requires careful evaluation of initial service commitments and NRC/NRC-related logistics for source handling.

• MASEP Medical Science & Technology Development Co. Ltd. (Shenzhen, China)

  Strengths: Manufacturer of rotating gamma stereotactic systems (e.g., INFINI) with regulatory clearances in multiple markets. Strong focus on cost-efficient manufacturing and expanding international footprint.

  Strategic considerations: MASEP’s product positioning typically appeals to institutions seeking competitive acquisition pricing. Buyers should quantify the trade-offs between lower upfront cost and long-term support, clinical training, and regulatory interoperability in non-domestic markets.

• OUR United Corp. / OUR New Medical Technology (Shenzhen, China)

  Strengths: Developer of image-guided rotating gamma platforms (TaiChi, Gamma Master) with prior clearances in the U.S. and China. Emphasis on integrated imaging guidance and treatment planning workflow improvements.

  Strategic considerations: The TaiChi platform’s clearance history and integrated guidance suite make it attractive for centers prioritizing image-guided extracranial applications. Procurement teams should evaluate installation footprints and integration with existing oncology information systems.

Regulatory, reimbursement and capital equipment dynamics

Several industry dynamics materially affect 2026 decision-making:

• Regulatory clarity is improving. Multiple rotating gamma platforms have secured regulatory clearances in major jurisdictions, reducing approval risk for buyers. However, understanding the regulatory nuances around source licensing, transportation and institutional NRC/NMPA requirements remains essential to avoid deployment delays.
• Reimbursement frameworks are generally accommodative. Stereotactic radiosurgery procedures using cobalt-60 rotating systems are typically billable under established hospital SRS/SBRT codes in many markets, but actual revenue capture depends on local coding practices and documentation of clinical outcomes.
• Lifecycle and source-management matter. Rotating gamma architectures commonly employ thirty cobalt-60 sources with substantial aggregate activity. The rotational delivery model can reduce the complexity of source replacement compared with some static multi-source designs, but explicit contracts for source supply, regulatory compliance and disposal are critical commercial levers.

Top strategic imperatives for 2026

• Align procurement with clinical strategy. Prioritize investments that close clearly defined clinical gaps (e.g., specific extracranial indications, expedited patient throughput) rather than selecting on price alone.
• Prioritize evidence generation. Negotiate supplier support for registries and prospective studies at contract signature to accelerate payer acceptance and internal adoption.
• Structure service and source agreements defensively. Insist on transparent source replacement schedules, capped pricing for source management, and SLA-backed uptime commitments tied to clinical volumes.
• Design phased rollouts. Use pilot sites and shared-service models initially to build operational experience before scaling to system-wide deployments.
• Stress-test supplier continuity. Evaluate suppliers for regulatory track record, spare-part inventories, and cross-border logistics to mitigate installation and maintenance downtime risk.
• Embed TCO into approval gates. Require TCO and ROI projections rather than only CAPEX comparisons, incorporating procedure mix and anticipated reimbursement trajectories.

Conclusion — actionable next steps

For leaders setting 2026 capital plans, the RGS landscape offers a compelling mix of clinical potential and procurement complexity. PW Consulting’s Worldwide Rotating Gamma System market report equips stakeholders with the market-sizing, scenario modeling, vendor playbooks and operational templates necessary to convert opportunity into sustainable program performance. To preserve the integrity of our modeling and to support custom procurement guidance, detailed segment-level tables, vendor scorecards and financial models are available exclusively in the full report and subscription datasets. Visit our report page to access the complete intelligence pack and to schedule a strategy briefing with PW Consulting’s radiotherapy practice.

For detailed analysis of this topic, please visit the official page:Worldwide Rotating Gamma System (RGS) Market

Lacy Lee
Senior Marketing Manager
[email protected]
00852-95632430
PW Consulting: www.pmarketresearch.com